We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From Nov 2023 to May 2024
By Denny Jacob
Johnson & Johnson posted better-than-expected sales in the latest quarter, buoyed by growth in the United States.
The healthcare company posted earnings of $4.13 billion, or $1.70 a share, for the fourth quarter ended Jan. 1, up 28% from $3.23 billion, or $1.22 a share, a year earlier. Adjusted earnings were $2.29 a share, above analysts' estimates of $2.28.
Sales grew 7.3% to $21.4 billion from $19.94 billion. Analysts polled by FactSet expected $21 billion.
Sales in the U.S. grew 11% to $12.01 billion, while international sales edged up 2.9% to $9.39 billion.
For 2024, J&J maintained its outlook of operational sales growth in the range of 5% and 6% as well as adjusted operational earnings per-share between $10.55 and $10.75.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 23, 2024 06:55 ET (11:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
